Cargando...
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited to its very broad spectrum of inhibition of angioge...
Gardado en:
| Publicado en: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8165211/ https://ncbi.nlm.nih.gov/pubmed/34079777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S251729 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|